1-(2,3-dihydro-1,4-benzodioxine-6-carbonyl)piperidine

• ChemBase ID: 126766
• Molecular Formular: C14H17NO3
• Molecular Mass: 247.28968
• Monoisotopic Mass: 247.12084341
• SMILES: C1CCN(CC1)C(=O)c1cc2c(cc1)OCCO2
• Canonical SMILES: O=C(c1ccc2c(c1)OCCO2)N1CCCCC1
• InChI: InChI=1S/C14H17NO3/c16-14(15-6-2-1-3-7-15)11-4-5-12-13(10-11)18-9-8-17-12/h4-5,10H,1-3,6-9H2
• InChIKey: LJUNPHMOGNFFOS-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: 1-(2,3-dihydro-1,4-benzodioxine-6-carbonyl)piperidine
• IUPAC Traditional name: 1-(2,3-dihydro-1,4-benzodioxine-6-carbonyl)piperidine
• Synonyms: CX-546; CX-546; (2,3-Dihydro-1,4-benzodioxin-6-yl)-1-piperidinylmethanone; 1-[(2,3-Dihydro-1,4-benzodioxin-6-yl)carbonyl]piperidine; BDP 17; GR 87; CX 546; 1-(1,4-Benzodioxan-6-ylcarbonyl)piperidine; CX546

Database IDs

• CAS Number: 215923-54-9
• MDL Number: MFCD01860868
• PubChem SID: 24277960; 162221094
• PubChem CID: 2890
• Unique Ingredient Identifier: PV6YEC8983
• Wikipedia Title: CX-546

CALCULATED PROPERTIES

• H Acceptors: 3
• H Donor: 0
• LogD (pH = 5.5): 1.6347357
• LogD (pH = 7.4): 1.6347369
• Log P: 1.6347369
• Molar Refractivity: 68.0292 cm^3
• Polarizability: 25.959505 Å^3
• Polar Surface Area: 38.77 Å^2
• Rotatable Bonds: 1
• Lipinski's Rule of Five: true

PROPERTIES

Physical Property

• Solubility: DMSO: ≥10 mg/mL
• Apperance: white to off-white solid

Safety Information

• Storage Condition: protect from light
• German water hazard class: 3
• Personal Protective Equipment: Eyeshields, Gloves, type N95 (US), type P1 (EN143) respirator filter
• Storage Temperature: 2-8°C

Pharmacology Properties

• Legal Status: Investigational New Medicine
• Gene Information: human ... GRIA1(2890), GRIA2(2891), GRIA3(2892), GRIA4(2893)

Product Information

• Purity: ≥98% (HPLC)

DETAILS

Sigma Aldrich - C271

Biochem/physiol Actions
Positive AMPA glutamate receptor modulator.
Caution
Photosensitive

Toronto Research Chemicals - C858000

It is one of a series of AMPA modulators for the potential treatment of Alzheimer's disease, schizophrenia, and mild cognitive impairment (MCI). An ampakine drug that facilitates activation of glutamatergic AMPA receptors.

REFERENCES

• Partin, K., et al.: J. Neurosci.,16, 6634 (1996)
• Vanover, K., et al.: Eur. J. Pharmacol., 332, 115 (1996)
• Moser, P., et al.: Brain Res. Rev., 33, 275 (1996)
• Kinney, G., et al.: J. Pharmacol. Exp. Ther., 306, 116 (1996)